IQVIA Holdings (IQV) Q4 FY25 earnings call: guidance and Q&A

Can you address concerns about AI disrupting established businesses and explain why IQVIA views AI as an enabling technology rather than a threat?

Management clarified that IQVIA has been on the AI journey for a long time, viewing it as an opportunity. They emphasized that their proprietary, dynamic, and regulatory-compliant healthcare data, combined with deep domain expertise, makes their business resilient to generic AI disruption. They explained that AI agents are embedded in existing workflows to enhance productivity and that IQVIA's scale across clinical and commercial justifies the significant investment in AI.

“Overall, I would say AI agentification is a positive for our business across both clinical and commercial, and I understand it's hard to distinguish between us and other CROs, us and other information services provider.”

asked by Shlomo Rosenbaum · answered by Ari Bousbib

Please provide more details on the Cedar Gate acquisition, its value, fit within IQVIA, and specific revenue/profit contribution.

Management stated that Cedar Gate expands IQVIA's payer-provider analytics business, an area where they previously lacked scale in the U.S. Cedar Gate transforms healthcare data into insights for improved patient outcomes and provides analytics to payers. It had approximately $140 million in revenue and similar margins in 2024, utilizing 4 petabytes of data and covering 60 million lives.

“It's about -- in '24, it was about $125 million in revenue, and it has $35 -- somewhere $33 million of adjusted EBITDA. That's what I have in front of me, $32.7 million to be precise. So -- and 25 -- A little bit higher than that. [ 140 maybe ]? 140 and about [indiscernible] similar margins.”

asked by Eric Coldwell · answered by Ari Bousbib

Can you confirm if AI is accretive to IQVIA's long-term growth rates and comment on whether the improving R&DS environment suggests a return to a 1.2 book-to-bill ratio in 2026?

Management reiterated that AI agentification is a positive and accretive to the business, emphasizing IQVIA's unique data assets and domain expertise. For R&DS, they noted strong demand indicators like double-digit growth in qualified pipelines and RFP flow, and improved win rates. While not providing a specific book-to-bill projection, they indicated that the demand environment is strong and funding has returned.

“AI agentification is a positive -- has been a positive, will continue to be a positive for us. IQVIA has the largest proprietary health care information assets in the world and is the foundation of our value to clients.”

asked by Justin Bowers · answered by Ari Bousbib

Have you observed any changes in large pharma behavior regarding AI for trial efficiency that might impact demand for your services, and what is the expected cadence of profitability for the upcoming year?

Management stated that large pharma's use of AI for trial efficiency aligns with IQVIA's long-standing strategy and creates partnership opportunities, not a threat to demand. They clarified that most large pharma AI efforts are upstream in discovery, which doesn't directly impact IQVIA's clinical trial business. Regarding profitability, Ron Bruehlman noted that the Q4 gross margin decline was due to strong pass-through growth, which is expected to moderate in 2026, leading to flat overall EBITDA margins, with SG&A margin continuing to improve due to productivity.

“No, nothing different with respect to large pharma AI efforts and the idea that clinical trials can be made more efficient with AI. We've been talking about this for a long time.”

asked by Elizabeth Anderson · answered by Ari Bousbib

Can you discuss the trajectory of pass-throughs and their impact on margin, and how IQVIA monetizes efficiency gains, particularly in the context of historical reprocurement by pharma clients?

Ron Bruehlman confirmed that strong pass-through growth was the biggest driver of the Q4 gross margin decline and is expected to moderate in 2026. Ari Bousbib acknowledged that productivity gains are shared with clients long-term. He indicated that historical reprocurements primarily determined rates, implying that price pressure was a way for pharma to extract value, but efficiency gains are also achieved through program-by-program discussions.

“Biggest driver of the gross margin decline you saw was very strong pass-through growth in the quarter, okay? And there's some mix -- product mix impact that gets into that as well. Now as we go into next year, you saw we're guiding towards flat overall EBITDA margins and the pass-through growth will moderate going into next year into 2026.”

asked by David Windley · answered by Ronald Bruehlman